Skip Navigation

DRUG RECORD

 

FONDAPARINUX

OVERVIEW
Fondaparinux

 

Introduction

Fondaparinux is a synthetic inhibitor of Factor Xa which given by injection and is used as an anticoagulant to treat as well as prevent venous thromboembolism.  Fondaparinux has been associated with a low rate of serum aminotransferase elevations during therapy, but has not been implicated in cases of clinically apparent, idiosyncratic liver injury.

 

Background

Fondaparinux (fon" da par' in ux) is a synthetic inhibitor of Factor Xa which blocks the activity of this clotting factor indirectly by binding to and activating antithrombin III.  Fondaparinux is composed of five monomeric sugars that are identical to the sequence present in heparin that comprises the high affinity binding site for antithrombin III.  Unlike standard and low molecular weight heparins, however, fondaparinux is specific for Factor Xa and has no effect on thrombin or other clotting factors.  As a result, fondaparinux has a more predictable and reproducible anticoagulant effect and can be administered in a fixed dose once daily and does not require monitoring for anticoagulant effect.  Fondaparinux was approved for use in the United States in 2001 and current indications include prevention of deep vein thromboses in high risk individuals (such as after surgery or during immobilization) and active treatment of deep vein thrombosis with or without pulmonary embolism (in combination with warfarin).  Fondaparinux is available as solution for injection in prefilled syringes generically and under the brand name Arixtra.  The typical dose for prophylaxis of deep vein thrombosis is 2.5 mg subcutaneously once daily for 5 to 30 days.  The dose regimen for treatment of deep vein thrombosis and pulmonary embolism is 5 to 10 mg (based upon body weight) subcutaneously once daily for at least 5 days and until a stable INR is achieved with warfarin.  Side effects include bleeding and thrombocytopenia, but are less common than with heparin.  Noncoagulation related side effects are uncommon but can include anemia, hypokalemia, insomnia, confusion, dizziness, hypotension, rash and purpura.

 

Hepatotoxicity

Fondaparinux therapy is associated with a low rate of serum aminotransferase elevations during therapy, with levels above 3 times the upper limit of normal occurring in 1% to 3% of patients, a lower rate than occurs with heparin (~8%) or low molecular weight heparins (4% to 12%) but higher than occurs with placebo (<1%).  The liver test abnormalities during fondaparinux therapy were generally mild, not associated with jaundice or symptoms and not requiring drug discontinuation.  The abnormalities appear to resemble those that occur with heparin and the low molecular weight heparins.   A case reported of marked ALT and AST elevations without jaundice arising within 2 days of starting fondaparinux and resolving rapidly on stopping has been reported.  Fondaparinux has not been in wide clinical use, but cases of idiosyncratic clinically apparent liver injury have not been reported in the literature.

 

Mechanism of Injury

Fondaparinux may cause a similar direct, self-limited hepatotoxicity as occurs with the use of natural and low molecular weight heparins.  If fondaparinux causes idiosyncratic drug induced liver injury, the mechanism of this effect is not known.  Fondaparinux has little hepatic metabolism and does not affect CYP 450 enzyme activity in the liver.

 

Outcome and Management

The serum aminotransferase elevations that occur during fondaparinux therapy are usually self-limited and do not require dose modification or discontinuation of therapy.  No convincing instances of clinically apparent or severe acute liver injury have been linked to fondaparinux in the published literature.

 

Drug Class:  Antithrombotic Agents, Anticoagulants

 

Other Drugs in the Subclass, Anticoagulants:  Dabigatran, Desirudin, Apixaban, Edoxaban, Rivaroxaban, Heparins, Heparin, Dalteparin, Enoxaparin, Tinzaparin, Warfarin

 

Top of page


PRODUCT INFORMATION
Fondaparinux

 

REPRESENTATIVE TRADE NAMES
Fondaparinux – Generic, Arixtra®

 

DRUG CLASS
Antithrombotic Agents

 

COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

 

Top of page


DRUG CAS REGISTRY NUMBER MOLECULAR FORMULA STRUCTURE
Fondaparinux 104993-28-4 C31-H53-N3-O49-S8 Fondaparinux Chemical Structure

Top of page


REFERENCES
Fondaparinux

 

References updated:  26 March 2014

  1. Zimmerman HJ. Heparin. Drugs used in cardiovascular disease. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 639-412.  (Textbook of hepatotoxicity published in 1999 before availability of fondaparinux).

  2. De Marzio DH, Navarro VJ. Hepatotoxicity of cardiovascular and antidiabetic drugs. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 519-40.  (Review of hepatotoxicity of drugs used in cardiovasular disease; the heparins and fondaparinux are not discussed).

  3. Weitz JI.  Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 849-76.  (Textbook of pharmacology and therapeutics; fondaparinux is a synthetic five-saccharide analogue of the natural pentasaccharide sequence found in heparin).

  4. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833-40. PubMed Citation  (Analysis of 4 controlled trials of fondaparinux versus enoxaparin in 7237 patients after orthopedic surgery; rates of side effects were similar in the two groups, but rates of liver injury and ALT elevations were not mentioned). 

  5. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, et al.; Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 867-73. PubMed Citation  (Controlled trial of fondaparinux vs enoxaparin in 2205 patients with deep venous thromboses found similar efficacy and safety; no mention of ALT elevations or hepatotoxicity).

  6. Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundström, et al.; THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005; 293: 681-9. PubMed Citation  (Controlled trial of ximelagatran versus enoxaparin and warfarin in 2489 patients with deep vein thromboses; ALT elevations above 3 times ULN occurred in 9.6% of ximelagatran vs 2% of enoxaparin/warfarin treated patients, and at least one patient on ximelagatran developed clinically apparent liver injury).

  7. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M; PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005; 92: 1212-20. PubMed Citation  (Among 2048 patients treated with fondaparinux or dalteparin for 5 to 9 days, side effects were similar in the two groups; no discussion of liver injury or ALT elevations).

  8. Turpie AG. The safety of fondaparinux for the prevention and treatment of venous thromboembolism. Expert Opin Drug Saf 2005; 4: 707-21. PubMed Citation  (Review of clinical efficacy and safety of fondaparinux; ALT elevations above 3 times the ULN occurred in 1.3-2.6% of patients on fondaparinux compared to 0.7% on placebo, 3.9-12.3% on enoxaparin, and 8% on heparin; abnormalities were usually asymptomatic and not associated with bilirubin elevations).

  9. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, et al.; ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332: 325-9. PubMed Citation  (Controlled trial of fondaparinux versus placebo in 849 patients 60 years or older admitted for illness requiring bed rest, no discussion of liver injury or ALT elevations).

  10. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network  (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34. PubMed Citation  (Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, none were attributed to fondaparinux or other anticoagulants).

  11. Decousus H, Prandoni P, Mismetti P, Bauersachs RM, Boda Z, Brenner B, Laporte S, et al.; CALISTO Study Group. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med 2010; 363: 1222-32. PubMed Citation  (Among 3002 patients with superficial vein thrombosis in the legs treated with fondaparinux or placebo for 45 days, side effects were similar in the two groups; liver injury and ALT elevations not mentioned).

  12. Orostegui L, Medejel N, Kone-Paut I, Dreyfus M, Benhamou D. Fondaparinux (Arixtra *) hepatotoxicity in a 6 year-old child. J Hepatol 2013; 58: 195-8. PubMed Citation  (5 year old child with a thrombosed vascular malformation developed marked liver test abnormalities 30 hours after starting fondaparinux [bilirubin 0.6 mg/dL, ALT 509 U/L, AST 720 U/L, Alk P 278 U/L], resolving within 5 days of stopping and later tolerating enoxaparin).

Top of page

 

OTHER REFERENCE LINKS
Fondaparinux
  1. PubMed logoRecent References on Fondaparinux

  2. Clinical Trials logoTrials on Fondaparinux

Top of page